BIOTOXTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,600 KRW | -0.88% |
|
+3.90% | -9.09% |
| 2022 | Biotoxtech Co., Ltd.(KOSDAQ:A086040) dropped from S&P Global BMI Index | CI |
| 2021 | Biotoxtech Co., Ltd.(KOSDAQ:A086040) added to S&P Global BMI Index | CI |
| Sales 2022 | 37.29B 27.15M | Sales 2023 | 32.63B 23.76M | Capitalization | 98.11B 71.43M |
|---|---|---|---|---|---|
| Net income 2022 | 2.72B 1.98M | Net income 2023 | -4.88B -3.55M | EV / Sales 2022 | 3.69 x |
| Net Debt 2022 | 18.37B 13.37M | Net Debt 2023 | 20.55B 14.96M | EV / Sales 2023 | 3.64 x |
| P/E ratio 2022 |
43.8
x | P/E ratio 2023 |
-19.5
x | Employees | 221 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.48% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.88% | ||
| 1 week | +3.90% | ||
| Current month | -6.67% | ||
| 1 month | -6.67% | ||
| 3 months | -9.24% | ||
| 6 months | -4.92% | ||
| Current year | -9.09% |
1 week
5 400.00
5 990.00
1 month
5 190.006 270.00
Current year
5 190.007 430.00
1 year
5 190.009 160.00
3 years
5 190.0012 900.00
5 years
4 030.0022 350.00
10 years
2 790.0023 600.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Gu Kang
CEO | Chief Executive Officer | 68 | 99-12-31 |
Seok-Mo Kang
CTO | Chief Tech/Sci/R&D Officer | 39 | - |
Soo-Yong Jeong
BRD | Director/Board Member | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Gu Kang
CEO | Chief Executive Officer | 68 | 99-12-31 |
Dong-Il Kim
BRD | Director/Board Member | 56 | - |
Cheol-Beom Park
BRD | Director/Board Member | 61 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 5,600 | -0.88% | 61,897 |
| 24-04-29 | 5,650 | +3.10% | 502,364 |
| 24-04-26 | 5,480 | +0.74% | 20,747 |
| 24-04-25 | 5,440 | -0.91% | 17,790 |
| 24-04-24 | 5,490 | +1.10% | 16,359 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Biotoxtech Co., Ltd. is a Korea-based company engaged in the research of non-clinical evaluation business. The Company provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.09% | 64.46M | |
| +0.67% | 42.4B | |
| +46.85% | 40.04B | |
| -6.20% | 28.31B | |
| +6.55% | 24.94B | |
| -21.66% | 18.96B | |
| +29.96% | 12.3B | |
| -1.57% | 11.95B | |
| +16.03% | 11.32B | |
| -4.80% | 11.55B |
- Stock Market
- Equities
- A086040 Stock
